Literature DB >> 2393870

Neuropeptide Y expression in the developing adrenal gland and in childhood neuroblastoma tumors.

P S Cohen1, M J Cooper, L J Helman, C J Thiele, R C Seeger, M A Israel.   

Abstract

Neuropeptide Y (NPY) expression is limited to tissues of the central and peripheral nervous system. In the adrenal gland, NPY is found in a subset of cells of the adrenal medulla. Using in situ hybridization analysis, NPY mRNA expression was characterized during human fetal adrenal medullary development. We found a biphasic pattern of NPY mRNA expression during the development of the human adrenal medulla. NPY mRNA is detectable at the earliest evaluable time point (7.5 weeks of gestational age) through 18 weeks of gestational age, and is then not detectable until 8 months after birth. We also analyzed NPY mRNA expression in neuroblastoma tumors, which often arise in the adrenal medulla. Thirty-eight neuroblastoma tumors were analyzed for NPY mRNA expression using in situ hybridization. We found NPY mRNA expression in 30 of 38 tumors; 15 of 15 Stage IVS tumors from children under 1 year of age at diagnosis expressed NPY mRNA, whereas 0 of 4 Stage IV tumors from children less than 1 year of age at diagnosis expressed NPY mRNA. These data suggest that in children under 1 year of age at diagnosis, Stage IVS and Stage IV neuroblastoma may be marked by the presence or absence, respectively, of NPY mRNA expression. Moreover, since NPY is expressed for only a short period of time during embryogenesis, these tumors may arise from different neuroblast populations occurring during the course of adrenal medullary development.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2393870

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Neuropeptide Y as a Biomarker and Therapeutic Target for Neuroblastoma.

Authors:  Susana Galli; Arlene Naranjo; Collin Van Ryn; Jason U Tilan; Emily Trinh; Chao Yang; Jessica Tsuei; Sung-Hyeok Hong; Hongkun Wang; Ewa Izycka-Swieszewska; Yi-Chien Lee; Olga C Rodriguez; Chris Albanese; Joanna Kitlinska
Journal:  Am J Pathol       Date:  2016-10-12       Impact factor: 4.307

2.  Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.

Authors:  Jason U Tilan; Mark Krailo; Donald A Barkauskas; Susana Galli; Haifa Mtaweh; Jessica Long; Hongkun Wang; Kirsten Hawkins; Congyi Lu; Dima Jeha; Ewa Izycka-Swieszewska; Elizabeth R Lawlor; Jeffrey A Toretsky; Joanna B Kitlinska
Journal:  Cancer       Date:  2014-11-11       Impact factor: 6.860

3.  In vivo spontaneous neuronal to neuroendocrine lineage conversion in a subset of neuroblastomas.

Authors:  C Gestblom; J C Hoehner; F Hedborg; B Sandstedt; S Påhlman
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

4.  The arcuate nucleus and neuropeptide Y contribute to the antitumorigenic effect of calorie restriction.

Authors:  Robin K Minor; Miguel López; Caitlin M Younts; Bruce Jones; Kevin J Pearson; Robert Michael Anson; Carlos Diéguez; Rafael de Cabo
Journal:  Aging Cell       Date:  2011-04-05       Impact factor: 9.304

5.  Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

Authors:  C Lu; L Everhart; J Tilan; L Kuo; C-C J Sun; R B Munivenkatappa; A-C Jönsson-Rylander; J Sun; A Kuan-Celarier; L Li; K Abe; Z Zukowska; J A Toretsky; J Kitlinska
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

6.  Plasticity of neuroblastoma tumor cells to differentiate along a fetal adrenal ganglionic lineage predicts for improved patient survival.

Authors:  M J Cooper; S M Steinberg; J Chatten; A E Evans; M A Israel
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

Review 7.  Neuropeptide Y (NPY) in tumor growth and progression: Lessons learned from pediatric oncology.

Authors:  Jason Tilan; Joanna Kitlinska
Journal:  Neuropeptides       Date:  2015-10-26       Impact factor: 3.286

Review 8.  Targeting pediatric malignancies for T cell-mediated immune responses.

Authors:  C L Mackall; L J Helman
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.945

9.  Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance.

Authors:  M Czarnecka; E Trinh; C Lu; A Kuan-Celarier; S Galli; S-H Hong; J U Tilan; N Talisman; E Izycka-Swieszewska; J Tsuei; C Yang; S Martin; M Horton; D Christian; L Everhart; I Maheswaran; J Kitlinska
Journal:  Oncogene       Date:  2014-08-18       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.